HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marc Ladanyi Selected Research

MAP Kinase Kinase 1

2/2012Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
7/2008Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marc Ladanyi Research Topics

Disease

252Neoplasms (Cancer)
05/2022 - 01/2002
72Lung Neoplasms (Lung Cancer)
01/2022 - 08/2005
56Adenocarcinoma of Lung
01/2021 - 01/2005
37Sarcoma (Soft Tissue Sarcoma)
01/2022 - 07/2002
21Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 02/2006
18Adenocarcinoma
01/2020 - 01/2005
15Carcinogenesis
01/2022 - 01/2003
13Carcinoma (Carcinomatosis)
01/2021 - 08/2003
13Synovial Sarcoma (Synovioma)
12/2018 - 02/2002
12Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 06/2003
11Breast Neoplasms (Breast Cancer)
01/2022 - 08/2003
10Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 07/2010
9Neoplasm Metastasis (Metastasis)
10/2020 - 04/2008
9Mesothelioma
01/2020 - 06/2003
9Ewing Sarcoma (Sarcoma, Ewing)
02/2016 - 07/2002
8Malignant Mesothelioma
01/2021 - 02/2010
7Rhabdomyosarcoma
01/2022 - 10/2004
7Microsatellite Instability
01/2021 - 01/2017
6Genetic Translocation (Chromosomal Translocation)
04/2022 - 11/2002
6Disease Progression
01/2021 - 02/2006
6Osteosarcoma (Osteogenic Sarcoma)
11/2019 - 08/2004
4Prostatic Neoplasms (Prostate Cancer)
01/2022 - 11/2011
4Leiomyosarcoma
01/2021 - 01/2018
4Thyroid Neoplasms (Thyroid Cancer)
01/2021 - 06/2009
4Alveolar Soft Part Sarcoma
10/2011 - 06/2003
3Desmoplastic Small Round Cell Tumor
04/2022 - 01/2021
3Chondrosarcoma
01/2020 - 01/2003
3Brain Neoplasms (Brain Tumor)
01/2020 - 06/2015
3Melanoma (Melanoma, Malignant)
01/2019 - 07/2012
3Astrocytoma (Pilocytic Astrocytoma)
01/2019 - 02/2005
3Glioma (Gliomas)
01/2019 - 10/2010
3Glioblastoma (Glioblastoma Multiforme)
12/2018 - 06/2009
3Leukemia
01/2018 - 06/2003
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
07/2012 - 06/2003

Drug/Important Bio-Agent (IBA)

47ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2005
44Proteins (Proteins, Gene)FDA Link
01/2022 - 05/2002
44DNA (Deoxyribonucleic Acid)IBA
01/2022 - 09/2004
42Tyrosine Kinase InhibitorsIBA
01/2022 - 11/2006
41Phosphotransferases (Kinase)IBA
04/2022 - 01/2005
27Biomarkers (Surrogate Marker)IBA
01/2022 - 08/2003
25Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2020 - 01/2005
24Biological ProductsIBA
01/2022 - 01/2002
22Transcription Factors (Transcription Factor)IBA
04/2022 - 07/2002
19Gefitinib (Iressa)FDA Link
02/2015 - 01/2005
16RNA (Ribonucleic Acid)IBA
01/2021 - 09/2004
14ParaffinIBA
01/2022 - 06/2003
13Immune Checkpoint InhibitorsIBA
01/2022 - 01/2017
13Messenger RNA (mRNA)IBA
01/2021 - 08/2002
13Pharmaceutical PreparationsIBA
01/2021 - 12/2007
12Formaldehyde (Formol)FDA Link
01/2022 - 06/2003
12Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2015 - 06/2003
11Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 11/2008
10Cell-Free Nucleic AcidsIBA
01/2022 - 01/2017
9CrizotinibIBA
01/2021 - 10/2010
9Anaplastic Lymphoma KinaseIBA
01/2019 - 02/2012
8Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2022 - 08/2005
7AfatinibIBA
01/2022 - 10/2012
5Estrogen ReceptorsIBA
01/2022 - 09/2011
5Cathepsin KIBA
01/2022 - 09/2010
5AntigensIBA
11/2021 - 02/2002
5ChromatinIBA
01/2021 - 01/2012
5cabozantinibIBA
12/2020 - 06/2013
5tyrosine receptor (receptor, tyrosine)IBA
12/2019 - 11/2008
5Oncogene Proteins (Oncogene Protein)IBA
12/2018 - 04/2013
5Monoclonal AntibodiesIBA
08/2014 - 02/2002
4selpercatinibIBA
01/2022 - 12/2019
4human ERBB2 proteinIBA
03/2021 - 02/2012
4DesminIBA
01/2021 - 08/2013
4larotrectinibIBA
01/2020 - 01/2018
4osimertinibIBA
01/2020 - 01/2017
4Imatinib Mesylate (Gleevec)FDA Link
03/2015 - 06/2003
4AntibodiesIBA
09/2013 - 08/2005
4Keratins (Keratin)IBA
09/2010 - 08/2002
4SYT-SSX fusion proteinIBA
07/2006 - 01/2002
3Telomerase (Telomerase Reverse Transcriptase)IBA
05/2022 - 04/2003
3NucleotidesIBA
01/2022 - 07/2017
3MART-1 AntigenIBA
01/2022 - 11/2019
3LigandsIBA
01/2021 - 07/2012
3Cyclin D1IBA
01/2021 - 12/2007
3Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2021 - 01/2019
3Sirolimus (Rapamycin)FDA Link
01/2021 - 05/2011
3Mitogen-Activated Protein KinasesIBA
10/2018 - 11/2008
3AsbestosIBA
07/2017 - 09/2004
3MicroRNAs (MicroRNA)IBA
10/2016 - 08/2009
3Small Interfering RNA (siRNA)IBA
01/2016 - 08/2010
3Codon (Codons)IBA
03/2015 - 09/2008
3Insulin-Like PeptidesIBA
09/2014 - 03/2003
3EWS-FLI fusion proteinIBA
01/2012 - 07/2002
3Mucin-1 (CA 15-3 Antigen)IBA
09/2010 - 08/2002
3Threonine (L-Threonine)FDA Link
11/2008 - 11/2006
3Methionine (L-Methionine)FDA Link
12/2007 - 06/2003
3RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
03/2006 - 02/2002
3EnzymesIBA
07/2005 - 06/2003
2Hormones (Hormone)IBA
01/2022 - 10/2018
2Cetuximab (Erbitux)FDA Link
01/2022 - 06/2015

Therapy/Procedure

109Therapeutics
01/2022 - 06/2003
18Drug Therapy (Chemotherapy)
01/2022 - 12/2003
17Immunotherapy
01/2022 - 02/2002
4Precision Medicine
01/2022 - 12/2015
4Aftercare (After-Treatment)
01/2021 - 03/2008